Benzinga | Jul 30, 2020 08:09AM EDT

Benchmark Maintains Buy on Amedisys, Raises Price Target to $250

Benchmark maintains Amedisys (NASDAQ:AMED) with a Buy and raises the price target from $210 to $250.